The metered-dose inhaler

Drug Delivery to the Lung

Volumn , Issue , 2001, Pages 337-370

  O’Callaghan, Chris ^a   Wright, Paul ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010531118     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (107)

1. Bower C, Washington C, Purewal TS. Characterisation of surfactant effect on aggregates in model aerosol propellant suspensions. J Pharm Pharmacol 1996; 48:337–341.
2. Gonda I. Development of a systematic theory of suspension inhalation aerosols: I. A framework to study the effects of aggregation on the aerodynamic behaviour of drug particles. Int J Pharm 1985; 27:99–116.
3. Atkins PJ. The development of new solution metered dose inhaler delivery systems. Proceedings of the Second Conference on Respiratory Drug Delivery. Lexington, KY: University of Kentucky, 1991: 416–445.
4. Clark AR. PhD thesis. Loughborough University of Technology, 1991.
5. Clark AR. Medical aerosol inhalers: past, Present, and future. Aerosol Sci Technol 1995, 22:374–391.
6. Byron PR. Aerosol formulation, generation, and delivery using metered systems. In: Byron PR, ed. Respiratory Drug Delivery. Boca Raton, FL: CRC Press, 1990: 171–174.
7. Newman S, Pavia D, Clarke S. Improving the bronchial deposition of pressurised aerosols. Chest 1981; 80:909–911.
8. Newman S, Pavia D, Garland N, Clarke S. Effects of various inhalation modes on the deposition of radioactive pressurised aerosols. Eur J Respir Dis 1982; 63:57–65.
9. Newman SP, Bateman JRN, Pavia D, Clarke SW. In: Baron D, ed. Recent Advances in Aerosol Therapy. Brussels: UCB Pharmaceuticals, 1979:117–122.
10. Lawford P, MacKenzie D. Does inspiratory flow rate affect broncodilator response to an aerosol beta-2 agonist? Thorax 1981; 36:714.
11. Hindle M, Newton DA, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993; 48:607–610.
12. Dolovich M, Ruffin RA, Roberts R, Newhouse MT. Optimal delivery of aerosol through metered dose inhalers. Chest 1981; 80:911–915.
13. Thomas P, Williams T, Riley PA, Bradley D. Modifying delivery technique of fenoterol from a metered dose inhaler. Ann Allergy 1984; 52:279–281.
14. Newman SP, Pavia D, Clarke SW. How should a pressurised beta adrenergic bronchodilator be inhaled? Eur J Respir Dis 1981; 62:3–21.
15. Lawford P, MacKenzie F. Pressurised bronchodilator aerosol technique: influence of breath holding, time and relationship of inhaler to the mouth. Br J Dis Chest 1982; 76:229–233.
16. Chhabra SK. A comparison of closed and open mouthed techniques of inhalation of salbutamol metered dose inhaler. J Asthma 1994; 31:123–125.
17. Riley DJ, Liu RT, Edelman NH. Enhanced responses to aerosolised bronchodilator therapy in asthma using respiratory manoeuvres. Chest 1979; 76:501–507.
18. Riley DJ, Weitz BW, Edelman NH. The responses of asthmatic subjects to isoproterenol inhaled at differing lung volumes. Am Rev Respir Dis 1976; 114:509–515.
19. Lawford P, MacKenzie D. Pressurised aerosol technique. Lancet 1981; 1:1003–1004.
20. Heimer D, Shim C, Williams MH. The effect of sequential inhalations of metaproterenol aerosol in asthma. J Allergy Clin Immunol 1980; 66:75–77.
21. Moran F. Aerosol dosage forms and formulations. In: Moran F, Dolovitch MB, Newhouse MT, Newman SP, eds. Aerosols in Medicine, Principles, Diagnosis and Therapy, 2d ed. Amsterdam: Elsevier Science, 1993: 321–350.
22. Berg E. In vitro properties of pressurised metered done inhalers with and without spacer devices J Aerosol Med 1995; 8:S3–S11.
23. Cyr TD, Graham SJ, Lee KYR, Lovering E.G. Low first-spray drug content in albuterol metered dose inhalers. Pharm Res 1991; 8:658–660.
24. Byron PR. Dosing reproducibility from experimental albuterol suspension metered dose inhalers. Pharm Res 1994; 11:580–584.
25. Everard MT., Devadason SG, Summers QA, Le Souef PN. Factors affecting total and respirable “dose” delivered by a salbutamol metered dose inhaler. Thorax 1995; 50:746–749.
26. Schulze MD, Riebe MT, Martin NB, Ryder SM, Shurkus DD, Ashurst IC. Development and performance of a new HFA-based metered dose inhaler (MDI) system for salbutamol sulphate. Eur Respir J 1997; 10(suppl 25): 38S.
27. Weiss W, Bodenheimer S, Bergner A, et al. Metered dose inhalers: drug delivery over the life of a canister. JAMA 1993; 270:2050–2051.
28. Bergner A, Griesner WA, Bergner RK. Metered dose inhalers: the specified number of sprays. JAMA 1993; 269:1506.
29. Ogren RA, Baldwin JL, Simon RA. How patients determine when to replace their metered dose inhalers. Ann Allergy Asthma Immunol 1995; 75:485–489.
30. Williams DJ, Williams AC, Kruchek DG. Problems in assessing contents of metered dose inhalers. Br Med J 1993; 307:771–772.
31. Davies D. Pharmacokinetics of inhaled substances. Postgrad Med J 1975; 51:69–75.
32. Newman SP, Pavia D, Morean F, Sheahan NF, Clarke SW. Deposition of presssurised aerosols in the human respiratory tract. Thorax 1981; 36:52–55.
33. Short M, Singh C, Few J, Studdy P, Heaf P, Spiro S. The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent. Chest 1981; 80:918–921.
34. Pauwels R, Newman S, Borgstrom L. Airways deposition and airway effects of anti-asthma drugs delivered from metered dose inhalers. Eur Respir J 1997; 10:2127–2138.
35. Saunders KB. Misuse of inhaled bronchodilating agents. Br Med J 1965; 1:1037–1038.
36. Patterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients. Br Med J 1976; 1:76–77.
37. Epstein SW, Manning CPR, Ashley MJ, Corey PN. Survey of the clinical use of pressurised aerosol inhalers. Can Med Assoc J 1979; 120:813–816.
38. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986; 41:118–124.
39. De Blaquiere P, Christensen DB, Carter WB, Martin TR. Use and misuse of metered dose inhalers by patients with chronic lung disease. Am Rev Respir Dis 1989; 140:910–916.
40. Larsen JS, Hahn M, Ekholm B, Wick KA. Evaluation of conventional press and breathe metered dose inhaler technique in 501 patients. J Asthma 1994; 31:193–199.
41. Van Beerendonk I, Mesters I, Mudde AN, Tan TD. Assessment of the inhalation technique in outpatients with chronic obstructive pulmonary disease using a metered dose inhaler or dry powder device. J Asthma 1998; 35:273–279.
42. Kelling JS, Strohl KP, Smith RL, Altose MD. Physician knowledge of the use of canister nebulisers. Chest 1983; 83:612–614.
43. Guidry GG, Brown WD, Stogner SW, George RB. Incorrect use of metered dose inhalers by medical personnel. Chest 1992; 101:31–33.
44. Kesten S, Zive K, Chapman KR. Pharmacists’ knowledge and ability of use inhaled medication delivery systems. Chest 1993; 104:1737–1742.
45. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel’s knowledge of and ability to use inhaling devices: metered dose inhalers, spacer chambers, and breath actuated dry powder inhalers. Chest 1994; 105:111–116.
46. Amiravi I, Goren A, Pawlowski NA. What do paediatricians in training know about the correct use of inhalers and spacer devices? J Allergy Clin Immunol 1994; 99:669–675.
47. Amirav I, Goran A, Kravitz RM, Pawlowski NA. Physician targeted programme on inhaled therapy for childhood asthma. J Allergy Clin Immunol 1995; 95:818–823.
48. Armitage JM, Williams SJ. Inhaler technique in the elderly. Age Ageing 1988; 17:275–278.
49. Crompton GK. Problems patients have using pressurised aerosol inhalers. Eur J Respir Dis 1982; 19(Suppl):101–104.
50. Newman SP Aerosol deposition considerations in inhalation therapy. Chest 1985; 88:142S–160S.
51. Pedersen S, Ostergaard PA. Nasal inhalation as cause of inefficient pulmonary aerosol technique in children. Allergy 1983; 38:191–194.
52. Allen SC, Prior A. What determines whether an elderly patient can use a metered dose aerosol correctly? Br J Dis Chest 1986; 80:45–49.
53. Gray SL, Williams DM, Pullan CC, Sirgo MA, Bishop AL, Donohue JF. Characteristics predicting incorrect metered dose inhaler technique in older subjects. Arch Intern Med 1996; 156:984–988.
54. Horsley MG, Baille GR. Risk factors for inadequate use of pressurised aerosol inhalers. J Clin Pharm Ther 1988; 13:139–143.
55. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhalation techniques in elderly subjects. Chest 1993: 104:1332–1337.
56. Bryant DH, Pepys J. Bronchial reactions to aerosol inhalant vehicle. Br Med J 1976; 1:1319–1320.
57. Reisman RE. Asthma induced by adrenergic aerosols. J Allergy 1970; 46:162.
58. Nicklas RA. Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990; 85:959–964.
59. Yarborough J, Mansfield L, Ting S. Metered dose inhaler induced bronchospasm in asthmatic patients. Ann Allergy 1985; 55:25–27.
60. Wilkinson JRW, Roberts JA, Brading P, Holgate ST, Howarth PH. Paradoxical restriction in asthmatic patients after salmeterol by metered dose inhaler. Br Med J 1992; 305:931–932.
61. Jackson L, Stahl E, Holgate ST. Terbutaline via a pressurised metered dose inhaler (pMDI) and Turbuhaler in highly reactive asthmatic patients. Eur Respir J 1994; 7:1598–1601.
62. Selroos O, Lofroos AB, Pietinalho A, Riska H. Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma. Thorax 1994; 49:1228–1230.
63. Gong HR, Taskin DP, Calvarese BM. Alcohol induced bronchospasm in an asthmatic patient: pharmacologic evaluation of the mechanism. Chest 1981; 80:167–173.
64. Borgstrom L, Newman S. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDl or Turbuhaler. Int J Pharm 1993; 97:47–53.
65. Newman SP. Deposition and effects of inhalation aerosols. Thesis, Rahms Tryckeri, Lund, Sweden, 1983.
66. Crompton GK. Breath-activated aerosol. Br Med J 1971; 2:652–653.
67. Wallace WAH, Lenny J, Cooksey E, Greening AP, Crompton GK. Ability of patients with severe air flow limitation to trigger a new breath actuated inhaler. Thorax 1989; 44:318.
68. Baum EA, Design, development and testing of a new breath actuated inhaler. Inspiration, development in inhalational therapy; meeting proceedings. Medicine Publishing Foundation, 1988:20–30.
69. Newman S, Weisz A, Talace N, Clarke S. Improvement of drug delivery with a breath-actuated pressurised aerosol for patients with poor inhalation technique. Thorax 1991; 46:712–716.
70. Pederson S, Mortensen S. Use of different inhalational devices in children. Lung 1990; 168 (suppl):653–657.
71. Ruggins, NR, Milner AD, Swarbrick A. An assessment of a new breath actuated inhaler device in acutely wheezy children. Arch Dis Child 1993; 68:477–480.
72. Hardy J, Jasuja A, Frier M, Perkins A. Asmall volume spacer for use with a breathoperated pressurised metered dose inhaler. Int J Pharm 1996; 142:129–133.
73. Price DB, Pearce L, Powell SR, Shirley J, Sayers MK. Handling and acceptiability of the Easi-Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. Int J Clin Pract 1999; 53:31–36.
74. Howlett D. Determination and improvement of patients’ co-ordination with pMDIs: Drug delivery to the lungs IX. Aerosol Soc 1998; 184–187.
75. Colthorpe P, Farr SJ, Taylor G, Smith IJ, Wyatt, D. The pharmacokinetics of pulmonary delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm Res 1992; 9:764–768.
76. Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled metered dose inhaler. Thorax 1995; 50:639–644.
77. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radio active pressurised aerosols. Eur J Respir Dis 1982; 119 (suppl):57–65.
78. Newman SP, Clark AR, Talaee N, Clarke SW. Pressurised aerosol deposition in the human lung with and without an “open” spacer device. Thorax 1989; 44:706–710.
79. Pearson M, Lewis R, Watson J, Ayres J, Ibbotson G, Ryan D. Generic inhalers for asthma. Br Med J 1994; 309:1440.
80. Struke G. Generic inhalers for asthma: patients titrate dose against response. Br Med J 1995;310:602.
81. Clarke DJ, Gordon-Smith J, McPhate G, Clark G, Lipworth BJ. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax 1996; 51:325–326.
82. Kenyon CJ, Dewsbury NJ, Newman SP. Differences in aerodynamic particle size distributions of innovator and generic beclomethasone dipropionate aerosols used with and without a large-volume spacer. Thorax 1995; 50:846–850.
83. Schultz RK, Dupont RL, Ledoux KA. Issues surrounding metered dose valve technology: past, present and future perspectives. In: Respiratory Drug Delivery IV. Buffalo Grove, IL: Interpharm Press, 1994:211–219.
84. Ross D, Carlson S, June D. Comparison of a new HFA albuterol metered dose inhaler (MDI) to a marketed CFC albuterol MDI—effect of storage orientation, end of canister life and temperature on dosing consistency. Am J Respir Crit Care Med 1996; 153:A62.
85. Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med 1999; 12:151–160.
86. Tansey I. Technological development of Airomir (salbutamol sulphate in CFC-free system) MDI. Br J Clin Pract 1995; (suppl 79):13–15.
87. Leach C. Improved delivery of inhaled steroids to enlarge small airways. Respir Med 1998; 92(suppl A):3–8.
88. Harrison L, Leach C, Seale P. Improvement in topical lung vs systemic availability of bectomethasone dipropionate from an extra-fine aerosol formulation. Eur Respir J 1997; 10(suppl 25):349s.
89. Milanowski J, Qualtrough J, Perrin VL. Inhaled beclomethasone (BDP) with non- CFC propellant (HFA134a) is equivalent to BDP-CFC for the treatment of asthma. Respir Med 1999; 93:245–251.
90. Davies D. Pharmacokinetic studies with inhaled drugs. Eur J Respir Dis 1982; 63:67–72.
91. Borgstrom L, Nilsson M. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res 1990; 7:1068–1070.
92. Vidgren M, Karkaainen A, Akarjalainen P, Nuutinen J, Paronen P. In vitro and in vivo deposition of drug particles inhaled from pressurized aerosol and dry powder inhaler. Drug Dev Ind Pharm 1988; 14:2649–2665.
93. Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbohaler is twice that from a pressurised metered dose inhaler (pMDI). Eur Respir J 1994; 7:1839–1844.
94. Melchor R, Biddiscombe M, Mak V, Short M, Spiro S. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48:506–511.
95. Biddiscombe M, Melchor R, Mak V, et al. The lung deposition of salbutamol, directly labelled with technetium-99m, delivered by pressurised metered dose and dry powder inhalers. Int J Pharm 1993; 91:111–121.
96. Borgstrom L. Methodological studies on lung deposition. Evalutation of inhalational devices and absorption mechanisms. Comprehensive summaries of Uppsala disserations from the Faculty Pharmacy 105. Acta Univ Uppsala 1993; 1–51.
97. Newman S, Steed K, Hooper G, Kallen A, Borgstrom L. Comparison of gamma scintigraphy and pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurised metered dose inhaler. Pharm Res 1995; 12:231–236.
98. Farr S, Rowe A, Rubsamen R, Taylor G. Optimisation of aerosol inhalation from metered dose inhalers by use of a novel microprocessor controlled device. Pharm Res 1994; 11–158.
99. Newman S, Clarke S. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurised aerosol inhaler. Chest 1993; 103:1442–1446.
100. Newman S, Clark A, Talace N, Clarke S. Lung deposition of 5 mg of Intal from a pressurised metered dose inhaler assessed by radiotracer technique. Int J Pharm 1991; 74:203–208.
101. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50:105–110.
102. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49:321–327.
103. Milgrom H. Bender B. Ackerson L. Bowry P. Smith B. Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98(6/1):1051–1057.
104. Simmons M, Nides MA, Rand CS, Wise RA, Tashkin DP. Trends in compliance with bronchodilator inhaler use between follow up visits in a clinical trial. Chest 1996; 109(4):963–968.
105. Rubsman R. Intrapulmonary delivery of narcotics. Patent: WO 94/16755, 1994.
106. Wolf J. Electronic medication Chronolog device. Patent: WO 97/13553, 1997.
107. Rubasmen R. Intrapulmonary delivery of hematopoietic drug. Patent: WO 96/30068, 1996.